Phân tích tổng quan hệ thống về chi phí - hiệu quả của apixaban trong ngăn ngừa đột quỵ ở người mắc bệnh rung nhĩ=Systematic review analysis of the cost-effectiveness of apixaban in stroke prevention in people with atrial fibrillation

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Văn Thúy Hà

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Khoa học và Công nghệ Việt Nam, 2025

Mô tả vật lý: tr.75-80

Bộ sưu tập: Metadata

ID: 478474

Thêm vào giỏ

Mục tiêu của nghiên cứu nhằm tổng hợp các nghiên cứu phân tích chi phí - hiệu quả của thuốc apixaban so với các phác đồ điều trị hiện tại trong phòng ngừa đột quỵ ở người mắc rung nhĩ. Nghiên cứu sử dụng phương pháp tổng quan tài liệu một cách có hệ thống để đánh giá chi phí - hiệu quả của apixaban trong ngăn ngừa đột quỵ ở người mắc bệnh rung nhĩ trên các cơ sở dữ liệu PubMed, Thư viện Cochrane, ScienceDirect, Google Scholar. Kết quả cho thấy, có 16/19 nghiên cứu (chiếm 84,21%) chứng minh apixaban đạt chi phí - hiệu quả (bao gồm 4 nghiên cứu apixaban với aspirin, 6 nghiên cứu apixaban với warfarin, 1 nghiên cứu apixaban với edoxaban, 1 nghiên cứu apixaban với dabigatran và 4 nghiên cứu thực hiện trên nhiều phác đồ). Trong đó, 11/16 nghiên cứu nhận được các tài trợ liên quan đến Công ty Pfizer. Chỉ có 3 nghiên cứu (chiếm 15,79%) không đạt chi phí - hiệu quả, bao gồm apixaban so sánh với warfarin tại Na Uy, apixaban so sánh với dẫn xuất coumarin tại châu Âu (Anh) và apixaban so sánh với warfarin tại Canada. Trong 19 nghiên cứu, có 4 nghiên cứu được thực hiện tại các quốc gia và vùng lãnh thổ thuộc châu Á như: Nhật Bản, Ả Rập Xê Út, Đài Loan và Trung Quốc. Các nghiên cứu đều sử dụng mô hình Markov hoặc Markov cải tiến, 17/19 nghiên cứu sử dụng khung thời gian đời người.This study aims to synthesise studies on the cost-effectiveness of apixaban compared to current treatment regimens for stroke prevention in people with atrial fibrillation. This study uses a systematic literature review to evaluate the cost-effectiveness of apixaban in stroke prevention in people with atrial fibrillation across PubMed, The Cochrane Library, ScienceDirect, and Google Scholar databases. Results indicated that and 16 out of 19 studies (84.21%) demonstrated cost-effectiveness (including 6 regimens of apixaban with aspirin, 7 regimens of apixaban with warfarin, 3 regimens of apixaban with edoxaban, and 1 regimen of apixaban with dabigatran, rivaroxaban). Among them, 11 out of 16 studies received funding from Pfizer. Only 3 studies (15.79%) found apixaban not to be costeffective, including comparisons with warfarin in Norway, coumarin derivatives in Europe (UK), and warfarin in Canada. Among the 19 studies, 4 were conducted in Asian countries, including Japan, Saudi Arabia, Chinese Taipei, and China. All studies applied Markov or improved Markov models, and 17 out of 19 used a lifetime time frame

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR